Tuesday, September 25, 2007

Novartis Receives EU's Approval for Alzheimer's Patch

Filed under: Geriatrics , Neurology

Following FDA's decision to approve the Exelon skin patch from Novartis, the EU certifies it in Europe as well.

The European Union approval, coming soon after the US approval in July 2007, was based on results from the international IDEAL (Investigation of Transdermal Exelon in ALzheimer's disease) study, which involved nearly 1,200 patients with mild to moderate Alzheimer's disease... The patch showed similar efficacy to the highest doses of Exelon capsules, as well as significant improvement in memory and the ability to perform everyday activities compared to placebo... In addition, the IDEAL study demonstrated three times fewer reports of gastrointestinal side-effects (nausea and vomiting) with the patch than the oral form of the medication.

Press release: Exelon patch receives European Union approval, the first skin patch therapy to treat Alzheimer's disease ...

                (0)

Name:


Email Address
(will not be published):


URL:

Remember personal info?
(anonymous comments allowed)

Yes No

Comments:

Enter the above anti-spambot
Turing code:

Click the "Post" button only once!